Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

This article summarizes metabolic reprogramming in prostate cancer (PCa). Early PCa relies more on glycolysis.

SGLT2 inhibitors linked to lower hormone therapy failure in prostate cancer. Learn more about their potential role in improving treatment outcomes.

面对前列腺癌这一男性泌尿系统高发肿瘤，传统雄激素剥夺治疗 (ADT)虽是基石，但"大多数患者在接受ADT后约1年内进展为去势抵抗性前列腺癌" [1]。近年来，新型内分泌治疗药物的问世为临床带来革命性突破，显著延长患者生存期并改善生活质量。

SAN FRANCISCO, September 28, 2025 — A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression ...

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL ...

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate CancerPRINCETON, N.J., Jan.

Prostate cancer has four stages. These stages show how much the cancer has grown and spread in the body. Knowing the stage helps doctors choose the right treatment and understand the outlook. After ...

Prostate cancer is a type of cancer that starts in the prostate gland, that helps make semen. Most men don’t notice anything ...